ADC Therapeutics SA — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; it does not provide a clear standalone fourth-quarter results summary. ADC Therapeutics is a commercial-stage oncology biotechnology company whose primary marketed product is ZYNLONTA, approved in the U.S. for relapsed or refractory DLBCL after two or more prior lines of systemic therapy and conditionally approved in Europe.
Financial performance and position
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Product revenue, net | $69.1 million | $74.9 million | Down 7.8% |
| License revenue and royalties | $0.5 million | $135.0 million | Down 99.6% |
| Total revenue, net | $69.6 million | $209.9 million | Down 66.9% |
| Operating expenses | $235.5 million | $333.3 million | Down 29.3% |
| Loss from operations | $(166.0) million | $(123.3) million | Loss increased |
| Net loss | $(240.1) million | $(157.1) million | Loss increased 52.8% |
| Basic and diluted loss per share | $(2.94) | $(2.01) | |
| Net cash used in operating activities | $(118.7) million | $(138.3) million | Cash use decreased |
| Cash and cash equivalents, year-end | $278.6 million | $326.4 million | Down $47.8 million |
Cost of product sales was $2.5 million, equivalent to a high reported product-level gross margin before other operating costs; the filing notes inventory and manufacturing factors affect this measure. No consolidated gross-margin percentage is presented as a headline metric.
At December 31, 2023, current assets were $336.3 million and current liabilities were $67.7 million. Total liabilities were $503.0 million, compared with total assets of $354.8 million, resulting in a shareholders’ deficit of $148.2 million. The balance sheet reports a $303.6 million long-term deferred royalty obligation and $112.7 million in senior secured term loans; the royalty obligation also has a current portion.
Material changes and business developments
- ZYNLONTA U.S. net product revenue declined 7.8%. The company attributed the decrease to higher gross-to-net deductions, including discarded-drug and inflation rebates, lower volume amid commercialization-model changes and competition, partly offset by higher price.
- License revenue fell sharply because the $135.0 million reported in 2022 included upfront and milestone payments under the MTPC and Sobi agreements. In 2023, the company reported $0.5 million in royalties.
- Research and development expense fell 31.8% to $127.1 million, reflecting pipeline prioritization, partner cost-sharing, the pause in Cami development and lower share-based compensation. Selling and marketing expense declined 16.8%; general and administrative expense declined 35.0%.
- Operating cash use improved by $19.6 million year over year, while cash and cash equivalents declined. Financing cash flow included $73.1 million net proceeds from the HCR royalty financing after ZYNLONTA’s first commercial sale in Europe.
- Income tax expense rose to $39.1 million, primarily due to a $47.8 million valuation allowance on deferred tax assets associated with a change in the U.S. intercompany operating and transfer-pricing model.
Outlook, risks and unusual items
- Management said existing capital resources were sufficient to fund operations and capital requirements for more than 12 months after the filing date. The 2023 compensation discussion also cited extending the cash runway into the fourth quarter of 2025 through cost reductions and capital allocation; this is not formal financial guidance. No numerical revenue or earnings guidance is provided.
- LOTIS-5, the confirmatory Phase 3 trial of ZYNLONTA plus rituximab, was expected to complete enrollment in 2024. Higher-than-expected censoring may require enrollment beyond the originally planned 350 patients to reach the required progression-free-survival events. The independent monitoring committee recommended continuing the trial and reported no safety concerns at its January 2024 meeting.
- ZYNLONTA’s accelerated U.S. and conditional European approvals depend on confirmatory evidence of clinical benefit. Failure to confirm benefit could put those approvals at risk. In July 2023, the company discontinued a Phase 2 ZYNLONTA-plus-rituximab trial in unfit or frail, previously untreated DLBCL patients after safety data signaled potentially excessive respiratory-related events.
- The company discontinued ADCT-901 dose expansion after limited signs of efficacy and paused investment in preclinical ADCT-212. Cami development was paused while the company evaluated FDA feedback.
- ADCT-601 remains in early-stage development; the company reported early signs of antitumor activity in sarcoma, alongside adverse events in combination treatment. ADCT-602 is in Phase 1/2 development, with additional data expected in 2024.
- Debt and financing constraints are significant. The term loan bears variable interest, is secured by substantially all company assets and includes a minimum qualified-cash covenant of $60 million plus certain overdue payables, as well as a U.S. ZYNLONTA sales covenant under specified conditions. HCR receives royalties on specified ZYNLONTA and Cami sales or licensing proceeds, reducing future cash available to the company.
- Other key risks include continuing losses and possible need for additional capital; reliance on one marketed product, commercial partners and third-party manufacturers; competitive and reimbursement pressures; clinical, regulatory and product-safety uncertainty; and intellectual-property risks. The company believes it was a passive foreign investment company for U.S. tax purposes in 2023.
- Auditor PwC issued unqualified opinions on the financial statements and internal control over financial reporting. Its critical audit matters included valuation of the HCR royalty obligation and estimation of the discarded-drug rebate. The company reported no material litigation that it expected to adversely affect the business.
Most important facts for investors to verify
- ZYNLONTA sales trajectory, net pricing and gross-to-net deductions, especially the discarded-drug rebate and its reported $7.4 million year-end accrual.
- LOTIS-5 enrollment, censoring, event targets, timing and confirmatory results, and the implications for continued regulatory approval.
- Cash burn and runway relative to management’s stated outlook; covenant compliance and the terms and servicing cost of the secured loan.
- HCR royalty payments, deferred-obligation accretion and the potential impact of revised sales forecasts, milestones or a change of control.
- Progress, safety and efficacy evidence for ADCT-601, ADCT-602 and ZYNLONTA combination studies, alongside decisions to pause or discontinue other programs.
- Commercial execution and partner performance, including international approvals and royalties, and the company’s ability to finance continued operations without excessive dilution.